cerca CERCA
Sabato 22 Gennaio 2022
Aggiornato: 19:23
Temi caldi

acido cloridrico

SBI ALApharma Canada Inc., a Subsidiary of photonamic GmbH & Co. KG (Germany), Enrolls First Patient in Pivotal Phase 3 Clinical Trial of PD G 506 A (5-ALA HCl) and Eagle Fluorescence Imaging System™ for Breast Conserving Surgery

TORONTO, May 7, 2021 /PRNewswire/ -- photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) ("photonamic"), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) the leader in the  pharmaceutical development, translation and global commercialization of 5-aminolevulinic acid ("5-ALA") (*) today announces that its Canadian subsidiary SBI ALApharma Canada Inc. (Head office: Toronto, Canada; CE...

ora in
Prima pagina
articoli
in Evidenza